

# Suresh S Ramalingam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2757389/publications.pdf>

Version: 2024-02-01

243  
papers

29,939  
citations

16411

64  
h-index

5227

165  
g-index

250  
all docs

250  
docs citations

250  
times ranked

28262  
citing authors

#	ARTICLE	IF	CITATIONS
1	Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 113-125.	13.9	3,530
2	Osimertinib or Platinum-Pemetrexed in <i>EGFR</i> T790M-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 629-640.	13.9	2,631
3	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 378, 2093-2104.	13.9	2,469
4	Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2020-2031.	13.9	1,866
5	Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , 2020, 382, 41-50.	13.9	1,725
6	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncology</i> , 2015, 16, 257-265.	5.1	1,269
7	<i>KRAS</i> <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors. <i>New England Journal of Medicine</i> , 2020, 383, 1207-1217.	13.9	1,049
8	Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation. <i>New England Journal of Medicine</i> , 2021, 384, 2371-2381.	13.9	833
9	Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. <i>Science</i> , 2017, 355, 1423-1427.	6.0	753
10	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4993-4998.	3.3	614
11	CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated <i>EGFR</i> -Mutated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3290-3297.	0.8	515
12	Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database. <i>Journal of Clinical Oncology</i> , 2007, 25, 5570-5577.	0.8	488
13	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017, 35, 1288-1296.	0.8	470
14	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. <i>Annual Review of Medicine</i> , 2018, 69, 301-318.	5.0	432
15	Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 841-849.	0.8	423
16	Lung cancer: New biological insights and recent therapeutic advances. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 91-112.	157.7	413
17	Outcomes for Elderly, Advanced-Stage Non-Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. <i>Journal of Clinical Oncology</i> , 2008, 26, 60-65.	0.8	358
18	Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions. <i>Oncologist</i> , 2008, 13, 5-13.	1.9	313

#	ARTICLE	IF	CITATIONS
19	Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. <i>Journal of Clinical Oncology</i> , 2015, 33, 4106-4111.	0.8	265
20	Comparison of the toxicity profile of PD&#x2011; versus PD&#x2011; inhibitors in non&#x2011;small cell lung cancer: A systematic analysis of the literature. <i>Cancer</i> , 2018, 124, 271-277.	2.0	265
21	Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non&#x2011;Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 56-62.	0.8	259
22	Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3673-3679.	0.8	251
23	Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan&#x2011;Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non&#x2011;Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3337-3344.	0.8	247
24	Plasma ctDNA Analysis for Detection of the EGFR &#x2197;790M Mutation in Patients with Advanced Non&#x2011;Small&#x2011;Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1061-1070.	0.5	240
25	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016, 11, 613-638.	0.5	231
26	Lung Master Protocol (Lung-MAP)&#x2011;A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. <i>Clinical Cancer Research</i> , 2015, 21, 1514-1524.	3.2	205
27	Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2007, 13, 3605-3610.	3.2	183
28	Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?. <i>Journal of Clinical Oncology</i> , 2018, 36, 631-632.	0.8	165
29	Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2009, 4, 97-101.	0.5	160
30	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations&#x2011;The Lung Cancer Mutation Consortium (LCMC2). <i>Clinical Cancer Research</i> , 2018, 24, 1038-1047.	3.2	154
31	Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. <i>Journal of Thoracic Oncology</i> , 2019, 14, 876-889.	0.5	141
32	Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. <i>Cancer Letters</i> , 2016, 380, 494-504.	3.2	137
33	Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1610-1623.	5.1	136
34	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 165-183.	0.5	134
35	Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 222-229.	0.8	133
36	<i>HER2</i> mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. <i>Cancer</i> , 2017, 123, 4099-4105.	2.0	132

#	ARTICLE	IF	CITATIONS
37	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1369-1378.	5.1	124
38	Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4574-4580.	0.8	122
39	The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. <i>Cancer</i> , 2019, 125, 127-134.	2.0	120
40	Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. <i>Cancer</i> , 2019, 125, 892-901.	2.0	117
41	Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. <i>Cancer Cell</i> , 2015, 27, 852-863.	7.7	108
42	The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1434-1448.	0.5	107
43	National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 128-137.	0.4	105
44	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5439-5444.	3.2	104
45	Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. <i>Clinical Cancer Research</i> , 2017, 23, 6567-6579.	3.2	103
46	Clinicopathologic Features of Advanced Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1411-1422.	0.5	101
47	Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6644-6652.	3.2	100
48	Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. <i>Cancer Biology and Therapy</i> , 2009, 8, 1463-1469.	1.5	97
49	EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 601-611.	7.7	97
50	Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 373-380.	2.0	95
51	Immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Cancer</i> , 2018, 124, 248-261.	2.0	94
52	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. <i>Journal of Thoracic Oncology</i> , 2021, 16, 464-476.	0.5	93
53	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. <i>Cancer</i> , 2016, 122, 766-772.	2.0	92
54	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. <i>BMC Cancer</i> , 2019, 19, 857.	1.1	88

#	ARTICLE	IF	CITATIONS
55	Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 60-67.	0.9	88
56	Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4507-4512.	0.8	87
57	Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. <i>Journal of Clinical Oncology</i> , 2016, 34, 3992-3999.	0.8	87
58	Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. <i>Cancer Biology and Therapy</i> , 2008, 7, 1952-1958.	1.5	86
59	Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9000-9000.	0.8	86
60	Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. <i>Journal of Thoracic Oncology</i> , 2019, 14, 99-106.	0.5	82
61	Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1119-1136.	0.5	82
62	Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 111.	1.8	78
63	Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097). <i>Journal of Thoracic Oncology</i> , 2010, 5, 1279-1284.	0.5	74
64	Poly (<sc>ADP</sc>) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. <i>Cancer Medicine</i> , 2014, 3, 1579-1594.	1.3	74
65	Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. <i>Targeted Oncology</i> , 2021, 16, 165-176.	1.7	69
66	Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2016, 17, e57-e64.	1.1	68
67	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP) Tj ETQq1 1 0.784314 rgBT /Overlo 5.1 68		
68	Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1937-1944.	3.2	67
69	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. <i>Cancer</i> , 2020, 126, 575-582.	2.0	65
70	ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9513-9513.	0.8	65
71	Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. <i>Clinical Lung Cancer</i> , 2017, 18, 286-292.	1.1	64
72	A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 3456-3461.	3.2	63

#	ARTICLE	IF	CITATIONS
73	Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. <i>Nature Medicine</i> , 2021, 27, 1910-1920.	15.2	62
74	HPV-associated lung cancers: an international pooled analysis. <i>Carcinogenesis</i> , 2014, 35, 1267-1275.	1.3	57
75	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1368.	3.4	57
76	The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. <i>Cancer</i> , 2015, 121, E1-6.	2.0	55
77	Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 299-315.	1.2	55
78	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 45-50.	2.0	55
79	The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. <i>Cancer Letters</i> , 2012, 325, 139-146.	3.2	54
80	Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2014, 120, 3940-3951.	2.0	53
81	Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced $\beta$ -TrCP degradation. <i>Oncogene</i> , 2019, 38, 6270-6282.	2.6	53
82	Socioeconomic Risk Factors for Long-Term Mortality after Pulmonary Resection for Lung Cancer: An Analysis of More than 90,000 Patients from the National Cancer Data Base. <i>Journal of the American College of Surgeons</i> , 2015, 220, 156-168e4.	0.2	52
83	Nonclinical Factors Associated with 30-Day Mortality after Lung Cancer Resection: An Analysis of 215,000 Patients Using the National Cancer Data Base. <i>Journal of the American College of Surgeons</i> , 2015, 221, 550-563.	0.2	52
84	Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2058-2063.	3.2	52
85	ALK-positive non-small cell lung cancer: Mechanisms of resistance and emerging treatment options. <i>Cancer</i> , 2014, 120, 2392-2402.	2.0	50
86	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2066-2081.	0.5	49
87	Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1687-1695.	0.5	47
88	Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1489-1495.	0.5	46
89	Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 433-441.	0.8	45
90	Evaluating Intensity-Modulated Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer: Results From the National Cancer Data Base. <i>Clinical Lung Cancer</i> , 2016, 17, 398-405.	1.1	44

#	ARTICLE	IF	CITATIONS
91	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. <i>Oncologist</i> , 2020, 25, e528-e535.	1.9	44
92	Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress. <i>Clinical Lung Cancer</i> , 2021, 22, 371-375.	1.1	44
93	Racial disparities in squamous cell carcinoma of the oral tongue among women: A SEER data analysis. <i>Oral Oncology</i> , 2015, 51, 586-592.	0.8	43
94	Necitumumab in Metastatic Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2015, 1, 1293.	3.4	43
95	Targeting EGFR in lung cancer: Lessons learned and future perspectives. <i>Molecular Aspects of Medicine</i> , 2015, 45, 67-73.	2.7	42
96	Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 441-447.	0.6	42
97	ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. <i>Cancer</i> , 2020, 126, 1339-1350.	2.0	40
98	Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 369-372.	0.5	37
99	Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. <i>Cancer</i> , 2016, 122, 50-60.	2.0	37
100	Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. <i>Cancer</i> , 2010, 116, 3903-3909.	2.0	36
101	Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy. <i>Cancer</i> , 2017, 123, 3681-3690.	2.0	36
102	Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. <i>JCI Insight</i> , 2017, 2, e90487.	2.3	36
103	JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2022, 128, 65-74.	2.0	36
104	The Biology and Clinical Features of Non-small Cell Lung Cancers with EML4-ALK Translocation. <i>Current Oncology Reports</i> , 2012, 14, 105-110.	1.8	35
105	Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2012, 118, 164-172.	2.0	35
106	Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 3476-3485.	2.0	35
107	Overexpression of the base excision repair NTHL1 glycosylase causes genomic instability and early cellular hallmarks of cancer. <i>Nucleic Acids Research</i> , 2018, 46, 4515-4532.	6.5	35
108	Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. , 2020, 8, e001302.		34

#	ARTICLE	IF	CITATIONS
109	PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)â€”A PrECOG LLC study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9003-9003.	0.8	34
110	Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. <i>Journal of Thoracic Oncology</i> , 2020, 15, 138-143.	0.5	33
111	Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 805-816.	1.1	32
112	Overcoming acquired resistance of epidermal growth factor receptorâ€”mutant nonâ€”small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). <i>Cancer</i> , 2020, 126, 2024-2033.	2.0	32
113	Targeting KRAS-Mutant Nonâ€”Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 4208-4218.	0.8	30
114	Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1289-1301.	1.1	29
115	Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. <i>Cancer Research</i> , 2021, 81, 4822-4834.	0.4	29
116	Distinct phenotypic states and spatial distribution of CD8+ Tâ€”cell clonotypes in human brain metastases. <i>Cell Reports Medicine</i> , 2022, 3, 100620.	3.3	29
117	Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3633-3644.	0.8	27
118	Recent advances in targeted therapy for non-small cell lung cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 245-257.	1.5	26
119	Recent Advances in the Treatment of Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1056-1064.	0.5	26
120	Guideline-concordant Care Improves Overall Survival for Locally Advanced Nonâ€”Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis. <i>Clinical Lung Cancer</i> , 2017, 18, 706-718.	1.1	26
121	MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptorâ€”mutant lung cancers. <i>Cancer</i> , 2020, 126, 3788-3799.	2.0	26
122	Overcoming acquired resistance of EGFRâ€”mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. <i>Molecular Oncology</i> , 2020, 14, 882-895.	2.1	26
123	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)., 2021, 9, e002973.		26
124	Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9027-9027.	0.8	26
125	Stereotactic Body Radiotherapy for Early-stage Nonâ€”small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center Analysis. <i>Clinical Lung Cancer</i> , 2017, 18, 551-558.e6.	1.1	24
126	Modulation of Bax and mTOR for Cancer Therapeutics. <i>Cancer Research</i> , 2017, 77, 3001-3012.	0.4	24



#	ARTICLE	IF	CITATIONS
127	Health care disparities among octogenarians and nonagenarians with stage III lung cancer. <i>Cancer</i> , 2018, 124, 775-784.	2.0	24
128	A banner year for immunotherapy and targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 79-80.	12.5	24
129	A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1859-1868.	3.2	22
130	Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. <i>Lung Cancer</i> , 2015, 88, 80-84.	0.9	22
131	Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1098-1108.	0.5	21
132	Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. <i>Head and Neck</i> , 2019, 41, 1490-1498.	0.9	21
133	Cetuximab for the Treatment of Advanced Bronchioloalveolar Carcinoma (BAC): An Eastern Cooperative Oncology Group Phase II Study (ECOG 1504). <i>Journal of Clinical Oncology</i> , 2011, 29, 1709-1714.	0.8	20
134	Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): A systematic review. <i>Oral Oncology</i> , 2014, 50, 888-894.	0.8	20
135	Osimertinib in EGFR Mutation-Positive Advanced NSCLC. <i>New England Journal of Medicine</i> , 2018, 378, 1261-1263.	13.9	20
136	Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers. <i>Lung Cancer</i> , 2018, 123, 99-106.	0.9	20
137	The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations. <i>Translational Oncology</i> , 2019, 12, 705-713.	1.7	20
138	Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. <i>Molecular Cancer Research</i> , 2021, 19, 1622-1634.	1.5	19
139	Gene methylation biomarkers in sputum as a classifier for lung cancer risk. <i>Oncotarget</i> , 2017, 8, 63978-63985.	0.8	19
140	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. <i>Journal of Clinical Oncology</i> , 2022, 40, 3808-3816.	0.8	19
141	Advances in the Diagnosis and Treatment of Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 557-564.	1.9	18
142	ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9077-TPS9077.	0.8	18
143	Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence. <i>Cancer Prevention Research</i> , 2017, 10, 635-640.	0.7	17
144	CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e264-e268.	1.1	17

#	ARTICLE	IF	CITATIONS
145	Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. <i>Oncogene</i> , 2021, 40, 6653-6665.	2.6	17
146	Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer. <i>Cancer</i> , 2010, 116, 1344-1349.	2.0	16
147	Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database. <i>Clinical Lung Cancer</i> , 2019, 20, 484-493.e6.	1.1	16
148	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. <i>Clinical Lung Cancer</i> , 2018, 19, 331-339.	1.1	15
149	Radiation Therapy Is Associated With an Increased Incidence of Cardiac Events in Patients with Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 383-390.	0.4	15
150	Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis. <i>Theranostics</i> , 2021, 11, 3964-3980.	4.6	15
151	Characteristics and outcomes of patients (pts) with metastatic KRAS mutant lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC) database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9021-9021.	0.8	15
152	The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2009, 14, 412-424.	1.9	14
153	Discussing molecular testing in oncology care: Comparing patient and physician information preferences. <i>Cancer</i> , 2017, 123, 1610-1616.	2.0	14
154	Throwing More Cold Water on Heat Shock Protein 90 Inhibitors in NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 473-474.	0.5	14
155	Advances in Immunotherapy and Implications for Current Practice in Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 662-668.	1.4	14
156	High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9586-9586.	0.8	14
157	Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 369, 291-299.	1.3	13
158	Role of bevacizumab for the treatment of non-small-cell lung cancer. <i>Future Oncology</i> , 2007, 3, 131-139.	1.1	12
159	Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 5040-5049.	2.0	12
160	Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis. <i>Oncologist</i> , 2020, 25, e964-e975.	1.9	12
161	Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor. <i>PLoS ONE</i> , 2021, 16, e0254125.	1.1	12
162	Double immune checkpoint blockade in advanced NSCLC. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102980.	2.0	12

#	ARTICLE	IF	CITATIONS
163	Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells. <i>Oncoscience</i> , 2015, 2, 765-776.	0.9	12
164	MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
165	Hypogonadism related to crizotinib therapy. <i>Cancer</i> , 2012, 118, E1-2.	2.0	11
166	Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: A retrospective cohort study. <i>Lung Cancer</i> , 2014, 86, 350-357.	0.9	11
167	Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors. <i>Seminars in Oncology</i> , 2015, 42, 713-723.	0.8	11
168	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019, 37, 1198-1206.	1.2	11
169	Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. <i>Lung Cancer</i> , 2020, 150, 26-35.	0.9	11
170	Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. <i>Clinical Cancer Research</i> , 2020, 26, 5860-5868.	3.2	11
171	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). <i>Immunotherapy</i> , 2021, 13, 727-734.	1.0	11
172	Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003). <i>Journal of Thoracic Oncology</i> , 2011, 6, 1741-1745.	0.5	10
173	Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 83-99.	0.9	10
174	Using Metaphors to Explain Molecular Testing to Cancer Patients. <i>Oncologist</i> , 2017, 22, 445-449.	1.9	9
175	Immunotherapy in previously treated non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Disease</i> , 2018, 10, S422-S432.	0.6	9
176	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2497-2505.	3.2	9
177	Protocol of DREAM3R: DuRvalumab with chemotherapy as first-line treatment in advanced pleural Mesothelioma—a phase 3 randomised trial. <i>BMJ Open</i> , 2022, 12, e057663.	0.8	9
178	Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both. <i>Oncogene</i> , 2022, 41, 1691-1700.	2.6	9
179	Encorafenib plus binimetinib in patients with BRAF <sup>V600</sup> -mutant non-small cell lung cancer: phase II PHAROS study design. <i>Future Oncology</i> , 2022, 18, 781-791.	1.1	9
180	Second-Generation ALK Inhibitors: Filling the Non-MET-Gap. <i>Cancer Discovery</i> , 2014, 4, 634-636.	7.7	8

#	ARTICLE	IF	CITATIONS
181	Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. <i>Clinical Lung Cancer</i> , 2018, 19, 270-279.e3.	1.1	8
182	Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). <i>Clinical Lung Cancer</i> , 2020, 21, 520-526.	1.1	8
183	Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study. <i>Cancer Research</i> , 2021, 81, CT163-CT163.	0.4	8
184	Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis. <i>Cancer Letters</i> , 2021, 519, 141-149.	3.2	8
185	Surgical Outcomes for Early Stage Non-small Cell Lung Cancer at Facilities With Stereotactic Body Radiation Therapy Programs. <i>Chest</i> , 2022, 161, 833-844.	0.4	8
186	Molecularly-targeted therapies for non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2667-2679.	0.9	7
187	Impact of a Non-small Cell Lung Cancer Educational Program for Interdisciplinary Teams. <i>Chest</i> , 2018, 153, 876-887.	0.4	7
188	Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. <i>Oncology</i> , 2018, 95, 138-146.	0.9	7
189	Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1727-1737.	0.5	7
190	Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1. <i>Cancer Gene Therapy</i> , 2022, 29, 1558-1569.	2.2	7
191	American Society of Clinical Oncology Policy Brief: FDA's Regulation of Electronic Nicotine Delivery Systems and Tobacco Products. <i>Journal of Oncology Practice</i> , 2017, 13, 58-60.	2.5	6
192	DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells. <i>DNA Repair</i> , 2019, 79, 1-9.	1.3	6
193	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1228-1234.	2.9	6
194	RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100050.	0.6	6
195	YAP1 positive small-cell lung cancer subtype is associated with the T-cell inflamed gene expression profile and confers good prognosis and long term survival.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9019-9019.	0.8	6
196	Small-Cell Lung Cancer: New Directions for Systemic Therapy. <i>Journal of Oncology Practice</i> , 2016, 12, 119-120.	2.5	5
197	Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 640-650.e2.	1.1	5
198	Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. <i>Clinical Lung Cancer</i> , 2017, 18, 5-12.	1.1	5

#	ARTICLE	IF	CITATIONS
199	Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. <i>Cancer</i> , 2018, 124, 3586-3595.	2.0	5
200	Improving outcomes for brain metastases in EGFR mutated NSCLC. <i>Translational Lung Cancer Research</i> , 2019, 8, S355-S359.	1.3	5
201	GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2605-TPS2605.	0.8	5
202	Impact of concomitant fibrates on immunotherapy outcomes for advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2023, 12, 358-367.	1.3	5
203	The Role of Targeted Agents in the Treatment of Elderly Patients with Non-Small Cell Lung Cancer (NSCLC). <i>Current Treatment Options in Oncology</i> , 2008, 9, 313-325.	1.3	4
204	Assays for PD-L1 Expression. <i>JAMA Oncology</i> , 2017, 3, 1058.	3.4	4
205	Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414). <i>JTO Clinical and Research Reports</i> , 2021, 2, 100104.	0.6	4
206	A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. <i>Oncologist</i> , 2021, 26, 523-532.	1.9	4
207	Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 960-967.	0.5	4
208	The National Cancer Act of 1971: A seminal milestone in the fight against cancer. <i>Cancer</i> , 2021, 127, 4532-4533.	2.0	4
209	Minimize Toxicity or Preserve Efficacy? A Delicate Trade-Off in the Management of Older Patients With Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 534-536.	0.8	3
210	Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q. <i>Cancer</i> , 2020, 126, 3140-3150.	2.0	3
211	Interim results of prospective pilot phase II trial of concurrent anti-PD-1 and stereotactic radiosurgery (SRS) for melanoma and NSCLC patients with brain metastases (NCT02858869).. <i>Journal of Clinical Oncology</i> , 2020, 38, e22002-e22002.	0.8	3
212	A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21682-e21682.	0.8	3
213	Histone Deacetylase, Proteasome, and Heat Shock Protein Inhibitors for the Treatment of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, S458-S460.	0.5	2
214	Co-Occurrence Conundrum: Brain Metastases from Lung Adenocarcinoma, Radiation Necrosis, and Gliosarcoma. <i>Case Reports in Oncology</i> , 2021, 14, 487-492.	0.3	2
215	Clinical performance of a comprehensive novel liquid biopsy test for identifying non-small cell lung cancer (NSCLC) patients for treatment with osimertinib.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9553-9553.	0.8	2
216	Histone Deacetylase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2011, 6, S1808-S1809.	0.5	1

#	ARTICLE	IF	CITATIONS
217	Time to divest from tobacco-funded research. <i>Cancer</i> , 2015, 121, 2294-2295.	2.0	1
218	Lung cancer in China: The new frontier?. <i>Cancer</i> , 2015, 121, 3058-3060.	2.0	1
219	Early detection of lung cancer in China: The immediate imperative. <i>Cancer</i> , 2015, 121, 3055-3057.	2.0	1
220	Metastatic Lung Cancer: Emerging Therapeutic Strategies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 736-749.	0.8	1
221	A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer. <i>Cancer</i> , 2019, 125, 2148-2153.	2.0	1
222	Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504). <i>JTO Clinical and Research Reports</i> , 2021, 2, 100166.	0.6	1
223	Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6083-6083.	0.8	1
224	Adherence reporting in phase III trials of approved oral anticancer agents: A systematic review.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20596-e20596.	0.8	1
225	Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9560-9560.	0.8	1
226	Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9576-9576.	0.8	1
227	Health care disparities among octogenarians and nonagenarians with stage III lung cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18075-e18075.	0.8	1
228	Safety and efficacy of combining pembrolizumab and dose escalation/fraction de-escalation SRS for melanoma and NSCLC brain metastasis: Preliminary results from arm a of a prospective pilot trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21542-e21542.	0.8	1
229	Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100274.	0.6	1
230	Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. <i>Journal of Clinical Oncology</i> , 2022, 40, 2285-2287.	0.8	1
231	Lung cancer with translocation in the anaplastic lymphoma kinase gene. <i>Cancer</i> , 2012, 118, 4370-4371.	2.0	0
232	Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States. <i>World Journal of Oncology</i> , 2015, 6, 349-354.	0.6	0
233	Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, 377-386.	1.1	0
234	Reply to N. Hanna et al and L. Xie et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 771-772.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Cancer matters: Now more than ever!. <i>Cancer</i> , 2021, 127, 2174-2176.	2.0	0
236	Prophylactic cranial irradiation in patients ≥ 70 years old with limited stage small cell lung cancer: A Surveillance, Epidemiology, and End Results analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7589-7589.	0.8	0
237	Impact of prior radiation on survival in metastatic lung cancer ECOG-ACRIN trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9051-9051.	0.8	0
238	Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e15607-e15607.	0.8	0
239	SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9623-9623.	0.8	0
240	Utilization patterns of immune checkpoint inhibitors (ICI) for non-small cell lung cancer (NSCLC) within the veterans health administration (VHA).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21630-e21630.	0.8	0
241	EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?. <i>Translational Lung Cancer Research</i> , 2020, 9, 1720-1723.	1.3	0
242	Exploring the future of non-small cell lung cancer treatment. <i>Managed Care</i> , 2005, 14, 9-13; discussion 13-4.	0.3	0
243	The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells.. <i>American Journal of Cancer Research</i> , 2022, 12, 779-792.	1.4	0